Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.
"Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.
Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide
12-13
Strategy guide